Evidence map›Paper›PMID 38777143›Full record

ArticleThe Journal of biological chemistry2024

A novel gain-of-function phosphorylation site modulates PTPN22 inhibition of TCR signaling.

Chuling Zhuang, Shen Yang, Carlos G Gonzalez, Richard I Ainsworth, Sheng Li, Masumi Takayama Kobayashi, Igor Wierzbicki, Leigh-Ana M Rossitto, Yutao Wen, Wolfgang Peti and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Fuzziness in enzymatic catalysis.Current opinion in structural biology · 2025
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Chuling ZhuangDepartment of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, California, USA.
Shen YangDepartment of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, California, USA; Department of Medicine, Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Carlos G GonzalezDepartment of Pharmacology, University of California, San Diego, California, USA; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, California, USA.
Richard I AinsworthDepartment of Medicine, Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Sheng LiDepartment of Medicine, University of California, San Diego, California, USA.
Masumi Takayama KobayashiDepartment of Molecular Biology and Biophysics, University of Connecticut Health, Farmington, Connecticut, USA.
Igor WierzbickiDepartment of Pharmacology, University of California, San Diego, California, USA; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, California, USA.
Leigh-Ana M RossittoDepartment of Pharmacology, University of California, San Diego, California, USA; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, California, USA.
Yutao WenDepartment of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, California, USA.
Wolfgang PetiDepartment of Molecular Biology and Biophysics, University of Connecticut Health, Farmington, Connecticut, USA.
Stephanie M StanfordDepartment of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, California, USA.
David J GonzalezDepartment of Pharmacology, University of California, San Diego, California, USA; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, California, USA.
Ramachandran MuraliDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Eugenio SantelliDepartment of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, California, USA; Department of Medicine, Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Nunzio BottiniDepartment of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, California, USA; Department of Medicine, Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. Electronic address: Nunzio.Bottini@cshs.org.

Funding

GRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5M
NIGMS NIH HHS T32 GM007752
6 · The paper itself

Abstract

Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) is encoded by a major autoimmunity gene and is a known inhibitor of T cell receptor (TCR) signaling and drug target for cancer immunotherapy. However, little is known about PTPN22 posttranslational regulation. Here, we characterize a phosphorylation site at Ser

Indexed as

Protein Tyrosine Phosphatase, Non-Receptor Type 22Receptors, Antigen, T-CellSignal TransductionGain of Function MutationHEK293 CellsHumansJurkat CellsPhosphorylationT-LymphocytesProtein Tyrosine Phosphatase, Non-Receptor Type 22PTPN22 protein, humanReceptors, Antigen, T-Cellallosteric regulationautoimmunitycatalysisintrinsically disordered regionphosphoproteomicsphosphorylationPTPN22T cell receptortranscriptomicstyrosine phosphatase

Identifiers

PMID38777143
PMCPMC11237943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.